Phesgo 600mg/600mg Injection

About

Phesgo 600mg/600mg Injection is a fixed-dose combination of pertuzumab and trastuzumab, two monoclonal antibodies, administered subcutaneously for the treatment of HER2-positive breast cancer. Both pertuzumab and trastuzumab target the human epidermal growth factor receptor 2 (HER2) protein, which is overexpressed in some aggressive breast cancers. Trastuzumab binds to subdomain IV of the HER2 extracellular domain, while pertuzumab binds to subdomain II, preventing HER2 dimerization and subsequent signaling.

This dual HER2 blockade provides a more comprehensive inhibition of HER2-mediated signaling pathways, leading to enhanced anti-tumor activity compared to either agent alone. Phesgo is indicated for use in combination with chemotherapy for early and metastatic HER2-positive breast cancer, offering a convenient subcutaneous administration option that reduces treatment time compared to intravenous infusions. Patients should be monitored for cardiac dysfunction and infusion-related reactions.

Uses

• Adjuvant treatment of early HER2-positive breast cancer.
• Neoadjuvant treatment of early HER2-positive breast cancer.
• Treatment of metastatic HER2-positive breast cancer.
• Used in combination with chemotherapy regimens.

Directions For Use

Phesgo 600mg/600mg Injection is administered subcutaneously by a healthcare professional. The initial dose may be higher, followed by maintenance doses every three weeks.

Benefits

• Dual HER2 blockade for enhanced efficacy.
• Subcutaneous administration reduces treatment time.
• Effective in early and metastatic HER2-positive breast cancer.
• Improved pathological complete response rates.
• Convenient for patients and healthcare providers.
• Part of established treatment guidelines.

Side Effects

• Diarrhea
• Nausea
• Alopecia (hair loss)
• Fatigue
• Neutropenia
• Anemia
• Peripheral neuropathy
• Rash
• Musculoskeletal pain
• Cardiomyopathy (heart muscle weakness)
• Infusion-related reactions
• Hypersensitivity reactions

Safety Measures

• Alcohol - No specific contraindication, but alcohol may worsen general side effects like nausea or fatigue. Consult your doctor.
• Pregnancy - Phesgo can cause oligohydramnios and fetal renal impairment. Avoid use during pregnancy. Women of reproductive potential must use effective contraception.
• Breastfeeding - It is unknown if Phesgo is excreted in human milk. Due to potential harm to the infant, breastfeeding is not recommended during treatment and for 7 months after the last dose.
• Liver - No specific dose adjustment is required for hepatic impairment. However, monitor liver function as part of general patient management.
• Kidney - No specific dose adjustment is required for renal impairment. Monitor kidney function as part of general patient management.
• Lung - Monitor for signs of pulmonary toxicity, including dyspnea, cough, and fever. Discontinue if severe pulmonary adverse events occur.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.